Boston Scientific Equity method investments (Note 11) remained flat by 0.0% to $334.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 30.5%, from $256.00M to $334.00M. Over 4 years (FY 2020 to FY 2024), Equity method investments (Note 11) shows a downward trend with a -3.4% CAGR.
Growth indicates strategic expansion into partnerships, while a decline may signal divestment or poor performance of the investee.
This represents the company's investment in entities where it exercises significant influence but does not have full con...
Common in the mining sector for joint ventures; peers often use this to share risk in large-scale projects.
other_equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $264.00M | $266.00M | $259.00M | $226.00M | $212.00M | $207.00M | $188.00M | $166.00M | $206.00M | $220.00M | $219.00M | $211.00M | $207.00M | $256.00M | $278.00M | $358.00M | $334.00M | $334.00M |
| QoQ Change | — | +0.8% | -2.6% | -12.7% | -6.2% | -2.4% | -9.2% | -11.7% | +24.1% | +6.8% | -0.5% | -3.7% | -1.9% | +23.7% | +8.6% | +28.8% | -6.7% | +0.0% |
| YoY Change | — | — | — | — | -19.7% | -22.2% | -27.4% | -26.5% | -2.8% | +6.3% | +16.5% | +27.1% | +0.5% | +16.4% | +26.9% | +69.7% | +61.4% | +30.5% |